Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter

Molecular Therapy

Volumn 24, Issue 3, 2016, Pages 508-521

  Ji, Haiyan ^a   Jiang, Zhengtao ^a   Lu, Panpan ^a   Ma, Li ^b   Li, Chuan ^b   Pan, Hanyu ^a   Fu, Zheng ^a   Qu, Xiying ^a   Wang, Pengfei ^a   Deng, Junxiao ^a   Yang, Xinyi ^a   Wang, Jianhua ^b   Zhu, Huanzhang ^a  

^a FUDAN UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; SINGLE GUIDE RNA 4; SINGLE GUIDE RNA 5; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR; VP64 PROTEIN; GUIDE RNA; HYBRID PROTEIN; PROTEIN BINDING;

ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG SCREENING; EMBRYO; EXPRESSION VECTOR; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LATENT VIRUS INFECTION; LONG TERMINAL REPEAT; NONHUMAN; PROMOTER REGION; REPORTER GENE; RNA BINDING; RNA SEQUENCE; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; UPREGULATION; VIRUS REACTIVATION; BINDING SITE; CELL LINE; CRISPR CAS SYSTEM; GENE EXPRESSION; GENE ORDER; GENE VECTOR; GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; VIRUS ACTIVATION;

BASE SEQUENCE; BINDING SITES; CELL LINE; CRISPR-CAS SYSTEMS; GENE EXPRESSION; GENE EXPRESSION REGULATION, VIRAL; GENE ORDER; GENE TARGETING; GENES, REPORTER; GENETIC VECTORS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; RNA, GUIDE; TRANSCRIPTIONAL ACTIVATION; VIRUS ACTIVATION;

EID: 84960347655     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.7     Document Type: Article

References (49)

1. Liu, H, Ma, Y, Su, Y, Smith, MK, Liu, Y, Jin, Y, et al. (2014). Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-Analysis. Clin Infect Dis 59: 1495-1502
2. Sluis-Cremer, N. (2014). The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses 6: 2960-2973
3. Richman DD, Margolis, DM, Delaney M, Greene WC, Hazuda, D and Pomerantz, RJ. (2009). The challenge of finding a cure for HIV infection. Science 323: 1304-1307
4. Coiras, M, Lopez-Huertas, MR, Perez-Olmeda, M and Alcami, J. (2009). Understanding HIV-1 latency provides clues for the eradication of long-Term reservoirs. Nat Rev Microbiol 7: 798-812
5. Deeks, SG, Autran, B, Berkhout, B, Benkirane, M, Cairns, S, Chomont, N, et al. (2012). Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12: 607-614
6. Sgarbanti, M and Battistini, A. (2013). Therapeutics for HIV-1 reactivation from latency. Curr Opin Virol 3: 394-401
7. Xing, S and Siliciano, RF. (2013). Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 18: 541-551
8. Bae, KH, Kwon, YD, Shin, HC, Hwang, MS, Ryu, EH, Park, KS, et al. (2003). Human zinc fingers as building blocks in the construction of artificial transcription factors. Nat Biotechnol 21: 275-280
9. Beerli, RR, Dreier, B and Barbas, CF 3rd. (2000). Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci USA 97: 1495-1500
10. Wang, P, Qu, X, Wang, X, Zhu, X, Zeng, H, Chen, H, et al. (2014). Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5-LTR promoter. Gene Ther 21: 490-495
11. Wang, X, Wang, P, Fu, Z, Ji, H, Qu, X, Zeng, H, et al. (2015). Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells. AIDS Res Hum Retroviruses 31: 98-106
12. Cong, L, Ran, FA, Cox, D, Lin, S, Barretto, R, Habib, N, et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823
13. Prashant, M, Luhan, Y, Esvelt, KM, John, A, Marc, G, Dicarlo, JE, et al. (2013). RNAguided human genome engineering via Cas9. Science 339: 823-826
14. Liao, HK, Gu, Y, Diaz, A, Marlett, J, Takahashi, Y, Li, M, et al. (2015). Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 6: 6413
15. Jinek, M, East, A, Cheng, A, Lin, S, Ma, E and Doudna, J. (2013). RNA-programmed genome editing in human cells. Elife 2: e00471
16. Perez-Pinera, P, Kocak, DD, Vockley, CM, Adler, AF, Kabadi, AM, Polstein, LR, et al. (2013). RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10: 973-976
17. Cress, BF, Toparlak, OD, Guleria, S, Lebovich, M, Stieglitz, JT, Englaender, JA, et al. (2015). CRISPathBrick: Modular Combinatorial Assembly of Type II-A CRISPR Arrays for dCas9-Mediated Multiplex Transcriptional Repression in E. coli. ACS Synth Biol 4: 987-1000
18. Tanenbaum, ME, Gilbert, LA, Qi, LS, Weissman, JS and Vale, RD. (2014). A proteintagging system for signal amplification in gene expression and fluorescence imaging. Cell 159: 635-646
19. Konermann, S, Brigham, MD, Trevino, AE, Joung, J, Abudayyeh, OO, Barcena, C, et al. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517: 583-588
20. Hu, J, Lei, Y, Wong, WK, Liu, S, Lee, KC, He, X, et al. (2014). Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res 42: 4375-4390
21. Cheng, AW, Wang, H, Yang, H, Shi, L, Katz, Y, Theunissen, TW, et al. (2013). Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 23: 1163-1171
22. Qi, LS, Larson, MH, Gilbert, LA, Doudna, JA, Weissman, JS, Arkin, AP, et al. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152: 1173-1183
23. Marciniak, RA, Calnan, BJ, Frankel, AD and Sharp, PA. (1990). HIV-1 Tat protein transactivates transcription in vitro. Cell 63: 791-802
24. Wei, P, Garber, ME, Fang, SM, Fischer, WH and Jones, KA. (1998). A novel CDK9-Associated C-Type cyclin interacts directly with HIV-1 Tat and mediates its high-Affinity, loop-specific binding to TAR RNA. Cell 92: 451-462
25. Van Herreweghe, E, Egloff, S, Goiffon, I, Jady, BE, Froment, C, Monsarrat, B, et al. (2007). Dynamic remodelling of human 7SK snRNP controls the nuclear level of active P-TEFb. EMBO J 26: 3570-3580
26. Eberhardy, SR, Goncalves, J, Coelho, S, Segal, DJ, Berkhout, B and Barbas, CF 3rd. (2006). Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol 80: 2873-2883
27. Platt, EJ, Bilska, M, Kozak, SL, Kabat, D and Montefiori, DC. (2009). Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83: 8289-8292
28. Ding, D, Qu, X, Li, L, Zhou, X, Liu, S, Lin, S, et al. (2013). Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. Virology 440: 182-189
29. Qu, X, Wang, P, Ding, D, Li, L, Wang, H, Ma, L, et al. (2013). Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 41: 7771-7782
30. Wang, P, Qu, X, Wang, X, Liu, L, Zhu, X, Zeng, H, et al. (2013). As2O3 synergistically reactivate latent HIV-1 by induction of NF-B. Antiviral Res 100: 688-697
31. Jordan, A, Bisgrove, D and Verdin, E. (2003). HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868-1877
32. Duh, EJ, Maury, WJ, Folks, TM, Fauci, AS and Rabson, AB. (1989). Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 86: 5974-5978
33. Biancotto, A, Grivel, JC, Gondois-Rey, F, Bettendroffer, L, Vigne, R, Brown, S, et al. (2004). Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78: 10507-10515
34. Hsu, PD, Scott, DA, Weinstein, JA, Ran, FA, Konermann, S, Agarwala, V, et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31: 827-832
35. Perez, EE, Wang, J, Miller, JC, Jouvenot, Y, Kim, KA, Liu, O, et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816
36. Holt, N, Wang, J, Kim, K, Friedman, G, Wang, X, Taupin, V, et al. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-847
37. Gilbert, LA, Horlbeck, MA, Adamson, B, Villalta, JE, Chen, Y, Whitehead, EH, et al. (2014). Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159: 647-661
38. Perkins, ND, Edwards, NL, Duckett, CS, Agranoff, AB, Schmid, RM and Nabel, GJ. (1993). A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J 12: 3551-3558
39. Hilton, IB, Dippolito, AM, Vockley, CM, Thakore, PI, Crawford, GE, Reddy, TE, et al. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 33: 510-517
40. Ran, FA, Cong, L, Yan, WX, Scott, DA, Gootenberg, JS, Kriz, AJ, et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. Nature 520: 186-191
41. Kleinstiver, BP, Prew, MS, Tsai, SQ, Topkar, VV, Nguyen, NT, Zheng, Z, et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523: 481-485
42. Binz, HK, Amstutz, P, Kohl, A, Stumpp, MT, Briand, C, Forrer, P, et al. (2004). Highaffinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22: 575-582
43. Roshal, M, Zhu, Y and Planelles, V. (2001). Apoptosis in AIDS. Apoptosis 6: 103-116
44. Zhang, Y, Yin, C, Zhang, T, Li, F, Yang, W, Kaminski, R, et al. (2015). CRISPR/gRNAdirected synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep 5: 16277
45. Shan, L, Deng, K, Shroff, NS, Durand, CM, Rabi, SA, Yang, HC, et al. (2012). Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501
46. Schmidt, F and Grimm, D. (2015). CRISPR genome engineering and viral gene delivery: a case of mutual attraction. Biotechnol J 10: 258-272
47. Fine, EJ, Appleton, CM, White, DE, Brown, MT, Deshmukh, H, Kemp, ML, et al. (2015). Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Sci Rep 5: 10777
48. Saayman, SM, Lazar, DC, Scott, TA, Hart, JR, Takahashi, M, Burnett, JC, et al. (2015). Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Mol Ther 23: 488-498
49. Limsirichai, P, Gaj, T and Schaffer, DV. (2015). CRISPR-mediated activation of latent HIV-1 expression. Mol Ther 23: 499-508